上海三维制药公司研制的新型降血脂药——吉非罗齐原料及胶囊已于10月20日由上海市医药管理局组织通过鉴定。 吉非罗齐(Gemfibrozil)原由华纳—兰勃特公司于1982年首先在美国上市,商品名为Lopid,并被USP22版收载。目前该药已在40多个国家销售,在1992年世界药物销售额居 Shanghai three-dimensional pharmaceutical company developed a new hypolipidemic drug-gemfibrozil raw materials and capsules on October 20 by the Shanghai Medical Administration Organization passed the appraisal. Gemfibrozil originally by Warner - Lambert company first listed in the United States in 1982, under the trade name Lopid, and was the USP22 version. The drug is currently marketed in more than 40 countries, accounting for the world’s drug sales in 1992